Generalised dermatitis induced by pegylated interferon-α-2b in a patient infected with genotype-1 hepatitis C virus: Presentation of a case

Clinical Drug Investigation

Volumn 25, Issue 4, 2005, Pages 281-284

  Gallelli, L ^a   Ferraro, M ^b   Mauro, G F ^b   De Sarro, G ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b San Giovanni in Fiore Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; DESQUAMATION; EXFOLIATIVE DERMATITIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROVOCATION TEST; URTICARIA;

EID: 17844377964     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525040-00009     Document Type: Article

References (21)

1. Poynard T, Leroy V, Mathurin P, et al. Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig Dis Sci 1996 Dec; 41 (12 Suppl.): 99S-102S
2. Carithers Jr RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (3 Suppl.): 83S-8S
3. Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology 1997; 26 (3 Suppl. 1): 96S-100S
4. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54; 547-70
5. Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001 Feb; 3 (1): 30-7
6. Poynard T. Effect of pegylated interferon on liver histology. Drug Saf 2002; 2: 14-5
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-6
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
9. Cnudde F, Gharakhanian S, Luboinski J, et al. Cutaneous local necrosis following interferon injections [letter]. Int J Dermatol 1991; 30: 147
10. Gallelli L, Guadagnino V, Caroleo B, et al. Cutaneous ulceration induced by interferon alfa. Ann Pharmacother 2004; 38: 173-14
11. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32
12. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92
13. Sookoian S, Neglia V, Castano G, et al. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 1999; 135: 1000-1
14. Hadziyannis SJ. Skin diseases associated with hepatitis C virus infection. J Eur Acad Dermatol Venereol 1998; 10: 12-21
15. Romero M, Perez-Olmeda M, Garcia-Samaniego J, et al. Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Drug Saf 2004; 27 (1): 7-24
16. Lambert J, Jonlet F, Vanhooteghem O, et al. A non-infectious pyodermatitis: pyoderma gangrenosum. Rev Med Liege 2001; 56: 106-11
17. Guarneri C, Vaccaro M, Cannavo SP, et al. Erythematous-edematous- infiltrative plaque on the face: cutaneous angiolupoid leishmaniasis. Eur J Dermatol 2002; 12: 597-9
18. Noblesse I, Beylot-Barry M, Doutre MS, et al. Cutaneous manifestations of rickettsiosis. Ann Dermatol Venereol 2002; 129: 1199-203
19. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 Suppl. 1: 67-75
20. Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol 2004 Feb; 140 (2): 215-7
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug; 30 (2): 239-45